NEWCASTLE UPON TYNE, UK, 24th March 2021. QuantuMDx today announces it has raised £11 million in its latest funding round. Proceeds will be used to complete manufacturing and commercial scale up
Continue
NEWCASTLE UPON TYNE, UK, 24th March 2021. QuantuMDx today announces it has raised £11 million in its latest funding round. Proceeds will be used to complete manufacturing and commercial scale up
ContinueNEWCASTLE UPON TYNE, UK, 13 February 2021. QuantuMDx today welcomed the Prime Minister, Rt Hon Boris Johnson MP, for a tour of its purpose-built HQ in Newcastle upon Tyne. QuantuMDx has developed
ContinueNEWCASTLE UPON TYNE, UK, 7th February 2021. Statement from Jonathan O’Halloran, Chief Executive Officer, QuantuMDx: QuantuMDx welcomes the news from the Government announcing a drive to increase workplace testing in
ContinueConclusions verify QuantuMDx’ previous analyses of test performance Results confirm this is one of the most sensitive tests on the market Fulfils the requirements of the MHRA’s Target Product Profile
ContinueNEWCASTLE UPON TYNE, UK, 21 January 2021. QuantuMDx today announces the appointment of Diran Guiliguian as Chief Commercial Officer. Diran has over a decade of experience working within world-leading diagnostic
ContinueNEWCASTLE UPON TYNE, UK, 22 December 2020. QuantuMDx today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new variant
ContinueNEWCASTLE UPON TYNE, UK, 17 December 2020. QuantuMDx today announced it has invested over £11 million to scale up production of its flagship diagnostic device, Q-POC™ and disposable test cassette, to mass
ContinueOur Head of Assay Feasibility, Dr John Tyson presented an e-poster at ECCVID last month – the ESCMID Conference on Coronavirus. The e-poster focuses on the independent, multi centre, clinical performance
ContinueTitle: QuantuMDx SARS-CoV-2 RT-PCR Detection Assay – design, analytical and multi-centre evaluation of clinical performance White paper overview: After completing the development of our SARS-CoV-2 RT-PCR Detection Assay, QuantuMDx undertook
ContinueQuantuMDx Group today announces its SARS-CoV-2 detection assay has been CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within the European Union. QuantuMDx has now registered the
ContinueQuantuMDx Group today announces the launch of its sensitive SARS-CoV-2 assay for laboratory use, which delivers a result in approximately 70 minutes. Working with British manufacturing partner Biofortuna Limited, QuantuMDx
ContinueQuantuMDx today announces a business update and the appointments of Jonathan O’Halloran as Chief Executive Officer and Neil Butler as Chairman of the Board, as the company begins its transition
ContinueQuantuMDx is dedicated to making transformative, quality diagnostic technologies accessible to everyone, so that diseases can be detected and treated earlier, and transmission eradicated.
QuantuMDx UK
Lugano Building
57 Melbourne Street
Newcastle upon Tyne
NE1 2JQ
+44 (0) 870 803 1234
moc.xdmutnauq@ofni